This trial will test a new CAR T cell therapy for safety and to find the best dose in patients with relapsed or recurrent AML or high-risk MDS.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
2 Primary · 5 Secondary · Reporting Duration: Up to 15 years
1 Treatment Group
Dose Escalation and Dose Expansion of PRGN-3006
1 of 1
88 Total Participants · 1 Treatment Group
Primary Treatment: PRGN-3006 T Cells · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any openings still available to participate in this experiment?
"According to clinicaltrials.gov, this research endeavor is presently seeking participants and has been listed since May 20th 2019 with its most recent update on August 2nd 2022." - Anonymous Online Contributor
What objectives is this trial attempting to meet?
"According to the study sponsor, PGEN Therapeutics Inc., a subsidiary of Precigen, Inc., their primary outcome metric over 12 months is measuring Dose Limiting Toxicities (DLTs). Additionally, they are assessing secondary outcomes such as disease response in MDS patients by International Working Group 2006 Criteria and Disease Progression in AML Patients using ELN Response Criteria. They will also document Complete PRGN-3006 T cells remission with partial hematological recovery alongside Number of PRGN-3006 T Cells present after treatment with PRGN-3006." - Anonymous Online Contributor
What precautions should be taken when utilizing PRGN-3006 T Cells?
"The safety of PRGN-3006 T Cells is likely to be well documented given that this a Phase 1 trial; thus, it has been assigned a score of 1 according to our team at Power." - Anonymous Online Contributor
What is the current enrollment size of this clinical trial?
"Affirmative. Clinicaltrials.gov indicates that this medical experiment was first advertised on May 20th 2019 and last modified on August 2nd 2022, with a target of 88 participants over two different locations being sought out." - Anonymous Online Contributor